Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 667 participants.

Also called NCT01627340

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 667 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01627340
Other papers using this trial's data
  • Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus Human vaccines & immunotherapeutics, 2016-08-02 DOI, PubMed 27123743, PMC4994745 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01627340. Non-randomized; no masking; primary purpose prevention. Start 2012-07-24 (registry gives no type); primary completion 2013-12-18 (actual). Results posted on 2015-01-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
Condition
Hepatitis B
Intervention (Biological)
Engerix™-B vaccine
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01627340
Content hash
19c12115f7c2421a3c5f5312e0ad8b27d1322e1c36071b9a99978cb4d47b894b